Biocompatibility Testing: A Guide for Medical Device Manufacturers

Introduction 

Ensuring the biological safety of medical devices is a critical step in product development and regulatory approval. Medical devices that come into contact with the human body must be evaluated to ensure they do not cause adverse biological reactions. ISO 10993-1 serves as the internationally recognized framework for biological evaluation and biocompatibility testing of medical devices. 

At METS Lab, we support manufacturers, importers, and healthcare innovators with comprehensive biocompatibility testing solutions designed to meet international regulatory requirements and help accelerate market access. 

What Is ISO 10993-1? 

ISO 10993-1, “Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing Within a Risk Management Process,” provides a risk-based framework for assessing the biological safety of medical devices. 

The standard requires manufacturers to evaluate: 

• Device materials and composition 
• Nature of body contact 
• Duration of patient exposure 
• Manufacturing processes 
• Potential biological risks 

Rather than requiring the same tests for every device, ISO 10993-1 uses a scientific risk assessment approach to determine the appropriate biological endpoints and testing requirements. 

Why Is Biocompatibility Testing Important? 

Medical devices interact directly or indirectly with patients through skin, tissue, blood, or bodily fluids. Inadequately evaluated materials may lead to: 

• Cytotoxicity 
• Skin irritation 
• Allergic sensitization 
• Systemic toxicity 
• Genotoxicity 
• Implant-related tissue reactions 
• Blood compatibility issues 

Biocompatibility testing helps identify and mitigate these risks before products reach the market, protecting patients and supporting regulatory approval. 

Key Components of an ISO 10993-1 Biological Evaluation 

Material Characterization 

A thorough understanding of raw materials, additives, coatings, and manufacturing processes forms the foundation of biological risk assessment. 

Device Contact Classification 

Devices are categorized based on: 

• Surface-contacting devices 
• External communicating devices 
• Implant devices 

Exposure duration is classified as: 

• Limited exposure (≤24 hours) 
• Prolonged exposure (24 hours–30 days) 
• Long-term exposure (>30 days) 

Biological Risk Assessment 

Existing data, published literature, clinical history, and previous testing results are reviewed to identify potential biological hazards and determine testing needs. 

Targeted Biocompatibility Testing 

When data gaps exist, specific tests are conducted to evaluate relevant biological endpoints. 

Common Biocompatibility Tests 

Depending on device type and intended use, testing may include: 

Cytotoxicity Testing 

Evaluates whether device materials cause toxic effects on living cells. 

Sensitization Testing 

Assesses the potential for allergic or hypersensitivity reactions. 

Irritation Testing 

Determines whether the device causes local irritation to skin or tissue. 

Systemic Toxicity Testing 

Evaluates harmful effects that may occur throughout the body following exposure. 

Hemocompatibility Testing 

Examine interactions between the device and blood for cardiovascular and blood-contacting devices. 

Genotoxicity Testing 

Assesses the potential for genetic damage caused by substances released from device materials. 

The Growing Importance of Chemical Characterization 

Regulatory authorities increasingly expect manufacturers to support biological evaluations with chemical characterization studies. 

Chemical characterization identifies extractables and leachables that may migrate from device materials during clinical use. Combined with toxicological risk assessment, this approach often provides stronger scientific justification while reducing unnecessary testing. Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER) 

Successful ISO 10993 compliance requires comprehensive documentation. 

Biological Evaluation Plan (BEP) 

The BEP defines: 

• Device description 
• Intended use 
• Risk assessment strategy 
• Biological endpoints 
• Testing approach 

Biological Evaluation Report (BER) 

The BER summarizes: 

• Available evidence 
• Testing results 
• Risk assessment conclusions 
• Overall biocompatibility determination 

These documents are essential components of regulatory submissions and technical files. 

How METS Lab Supports Medical Device Manufacturers 

METS Lab provides comprehensive biocompatibility testing and biological evaluation services to support medical device compliance and patient safety. Our technical experts work closely with manufacturers to develop risk-based testing strategies aligned with ISO 10993 requirements and global regulatory expectations. Our services help clients: 

• Identify biological risks early in development 
• Generate reliable safety data 
• Support FDA and international regulatory submissions 
• Reduce approval delays 

Demonstrate compliance with ISO 10993 standards